Arca Biopharma Stock Today

ABIO
 Stock
  

USD 2.41  0.04  1.63%   

Market Performance
4 of 100
Odds Of Distress
Less than 5
Arca Biopharma is selling for 2.41 as of the 16th of August 2022. This is a -1.63 percent decrease since the beginning of the trading day. The stock's open price was 2.45. Arca Biopharma has under 5 % chance of experiencing financial distress over the next 2 years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Arca Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of July 2022 and ending today, the 16th of August 2022. Please note, there could be an existing legal relationship between Arca Biopharma (ABIO) and ARCA BIOPHARMA INC (HYSQ). Click here to learn more.
CUSIP
00211Y100
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of August 1997
Category
Healthcare
Classification
Health Care
ISIN
US00211Y5069
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.41 M outstanding shares of which 71.36 K shares are presently shorted by private and institutional investors with about 1.51 trading days to cover. More on Arca Biopharma
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Arca Biopharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Arca Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arca Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (16.81 M) with profit before overhead, payroll, taxes, and interest of 28.37 M.
Arca Biopharma currently holds about 46.44 M in cash with (16.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Arca Biopharma has a very weak financial position based on the latest SEC disclosures
Latest headline from www.fiercebiotech.com: Pieris puts phase 2 cancer drug out on chopping block - FierceBiotech
New SymbolABIO1
Related EntityHYSQ (ARCA BIOPHARMA INC)
President CEO, DirectorMichael Bristow
Fama & French Classification
Average Analyst Recommendation
Analysts covering Arca Biopharma report their recommendations after researching Arca Biopharma's financial statements, talking to executives and customers, or listening in on Arca Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Arca Biopharma. The Arca Biopharma consensus assessment is calculated by taking the average forecast from all of the analysts covering Arca Biopharma.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Arca Biopharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Arca Biopharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Very WeakDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares15 M13.9 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted15 M13.9 M
Significantly Up
Increasing
Slightly volatile
Total Assets59.3 M54.9 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities3.1 M3.9 M
Significantly Down
Increasing
Slightly volatile
Current Assets58.7 M54.4 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities2.8 M3.5 M
Significantly Down
Increasing
Slightly volatile
Total Debt368.3 K383 K
Sufficiently Down
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Arca Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Arca Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Arca Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arca Biopharma's financial leverage. It provides some insight into what part of Arca Biopharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Arca Biopharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Arca Biopharma deploys its capital and how much of that capital is borrowed.
Liquidity
Arca Biopharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 329 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Arca Biopharma has a current ratio of 16.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Arca Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Arca Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arca Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arca Biopharma to invest in growth at high rates of return. When we think about Arca Biopharma's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(19.26 Million)
Arca Biopharma (ABIO) is traded on NASDAQ Exchange in USA. It is located in 10170 Church Ranch Way and employs 17 people. Arca Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 34.87 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arca Biopharma's market, we take the total number of its shares issued and multiply it by Arca Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Arca Biopharma conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 14.41 M outstanding shares of which 71.36 K shares are presently shorted by private and institutional investors with about 1.51 trading days to cover. Arca Biopharma currently holds about 46.44 M in cash with (16.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Arca Biopharma Probability Of Bankruptcy
Ownership
Arca Biopharma retains a total of 14.41 Million outstanding shares. 30% of Arca Biopharma outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Arca Biopharma Ownership Details

Arca Biopharma Stock Price Odds Analysis

What are Arca Biopharma's target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Arca Biopharma jumping above the current price in 90 days from now is about 39.54%. The Arca Biopharma probability density function shows the probability of Arca Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Arca Biopharma has a beta of 0.4053. This suggests as returns on the market go up, Arca Biopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Arca Biopharma will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0777, implying that it can generate a 0.0777 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 2.41HorizonTargetOdds Above 2.41
60.11%90 days
 2.41 
39.54%
Based on a normal probability distribution, the odds of Arca Biopharma to move above the current price in 90 days from now is about 39.54 (This Arca Biopharma probability density function shows the probability of Arca Biopharma Stock to fall within a particular range of prices over 90 days) .

Arca Biopharma Historical Income Statement

Arca Biopharma Income Statement is one of the three primary financial statements used for reporting Arca Biopharma's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Arca Biopharma revenue and expense. Arca Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Arca Biopharma Weighted Average Shares is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 15 Million. Weighted Average Shares Diluted is expected to rise to about 15 M this year, although the value of Consolidated Income will most likely fall to (19.8 M). View More Fundamentals

Arca Biopharma Stock Against Markets

Picking the right benchmark for Arca Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arca Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arca Biopharma is critical whether you are bullish or bearish towards Arca Biopharma at a given time.

Similar Equity Warning - ABIO

Arca Biopharma was forked

The entity Arca Biopharma with a symbol ABIO was recently forked. You can potentially use APPLIED BIOMETRICS INC with a symbol ABIO1 from now on.

Arca Biopharma Corporate Directors

Arca Biopharma corporate directors refer to members of an Arca Biopharma board of directors. The board of directors generally takes responsibility for the Arca Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Arca Biopharma's board members must vote for the resolution. The Arca Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Raymond Woosley - DirectorProfile
Daniel Mitchell - DirectorProfile
Linda Grais - Lead Independent DirectorProfile
Anders Hove - DirectorProfile

Invested in Arca Biopharma?

You need to understand the risk of investing before taking a position in Arca Biopharma. The danger of trading Arca Biopharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arca Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arca Biopharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arca Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Arca Biopharma information on this page should be used as a complementary analysis to other Arca Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Arca Biopharma Stock analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
35.3 M
Return On Assets
-0.19
Return On Equity
-0.32
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.